Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe-/- mice

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 427-435

  Burgmaier, Mathias ^a   Liberman, Ana ^a   Möllmann, Julia ^a   Kahles, Florian ^a   Reith, Sebastian ^a   Lebherz, Corinna ^a   Marx, Nikolaus ^a   Lehrke, Michael ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Atherosclerosis; GLP 1; Incretins; Plaque stability; Type 2 diabetes

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; COLLAGEN; GELATINASE B; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (28-37); GLUCAGON LIKE PEPTIDE 1 (9-37); GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DESCENDING AORTA; HIGH RISK PATIENT; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR LESION; WEIGHT GAIN;

ATHEROSCLEROSIS; GLP-1; INCRETINS; PLAQUE STABILITY; TYPE 2 DIABETES;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD GLUCOSE; COLLAGEN; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; INCRETINS; INFLAMMATION; LIPIDS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; TRANSGENES;

EID: 84888120953     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.033     Document Type: Article

References (30)

1. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
2. Burgmaier M., Heinrich C., Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. Diabet Med 2012.
3. Liu Z., Stanojevic V., Brindamour L.J., et al. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic beta-cells from glucolipotoxicity. JEndocrinol 2012, 213:143-154.
4. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEngl J Med 1998, 339:229-234.
5. Lehrke M., Marx N. Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 2011, 8:382-391.
6. Vittone F., Liberman A., Vasic D., et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012, 55:2267-2275.
7. Arakawa M., Mita T., Azuma K., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
8. Shah Z., Kampfrath T., Deiuliis J.A., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349.
9. Matsubara J., Sugiyama S., Sugamura K., et al. Adipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. JAm Coll Cardiol 2012, 59:265-276.
10. Hildebrandt M., Schabath R. SDF-1 (CXCL12) in haematopoiesis and leukaemia: impact of DPP IV/CD26. Front Biosci 2008, 13:1774-1779.
11. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55:10-16.
12. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
13. Ban K., Kim K.H., Cho C.K., et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
14. Tomas E., Stanojevic V., Habener J.F. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011, 167:177-184.
15. Tomas E., Wood J.A., Stanojevic V., et al. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul Pept 2011, 169:43-48.
16. Lebherz C., Gao G., Louboutin J.P., et al. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. JGene Med 2004, 6:663-672.
17. Bennett J., Duan D., Engelhardt J.F., et al. Real-time, noninvasive invivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 1997, 38:2857-2863.
18. Trinder P., Webster D. Determination of HDL-cholesterol using 2,4,6-tribromo-3-hydroxybenzoic acid with a commercial CHOD-PAP reagent. Ann Clin Biochem 1984, 21(Pt 5):430-433.
19. Virmani R., Burke A.P., Farb A., et al. Pathology of the vulnerable plaque. JAm Coll Cardiol 2006, 47:C13-C18.
20. Virmani R., Kolodgie F.D., Burke A.P., et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
21. Abu-Hamdah R., Rabiee A., Meneilly G.S., et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. JClin Endocrinol Metab 2009, 94:1843-1852.
22. Nikolaidis L.A., Elahi D., Shen Y.T., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
23. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2045-2051.
24. Tomas E., Wood J.A., Stanojevic V., et al. Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab 2011, 13:26-33.
25. Kitajima K., Marchadier D.H., Miller G.C., et al. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 2006, 26:1852-1857.
26. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
27. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
28. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAm Med Assoc 2002, 287:2570-2581.
29. Marx N., Kehrle B., Kohlhammer K., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710.
30. Ross R. Atherosclerosis-an inflammatory disease. NEngl J Med 1999, 340:115-126.